Skip to main content


Fig. 4 | BMC Infectious Diseases

Fig. 4

From: The therapeutic HIV Env C5/gp41 vaccine candidate Vacc-C5 induces specific T cell regulation in a phase I/II clinical study

Fig. 4

Vacc-C5-specific proliferative T cell responses. a Responses at week 1, 6, 15 and 26 in CD8+ (upper panel) and CD4+ (lower panel) T cell subsets. Data are given as medians, interquartile and overall ranges. Changes with p-values 0.10 or less are indicated. b Individual responses at week 1 (baseline), 6 (after initial immunisation), 15 (after1st boost) and 26 (after 2nd boost, end of study) in CD8+ (upper panel) and CD4+ (lower panel) T cell subsets

Back to article page